Reuter U, et al. Long-term efficacy and safety of erenumab: Results from 64 weeks of the LIBERTY study. IHC-OR-006. IHC 2019 5-8 sept. Dublin, Ierland.
Nieuwe cijfers Alzheimer Europe: aantal mensen met dementie in 2050 verdubbeld
feb 2020 | Dementie